Brief: Travere Therapeutics Q1 EPS USD -0.47 Vs. IBES Estimate USD -0.54
May 01 (Reuters) - Travere Therapeutics Q1 product sales USD 75.861 million vs. IBES estimate USD 77.6 million. Q1 operating expenses USD 124.406 million Q1 operating income USD -42.674 million vs. IBES estimate USD -47.2 million Q1 net income USD -41.226 million
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule